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ABSTRACT
Objectives: The objective of the present study is to assess whether a good buccodental status (evaluated by means of 
dentogingival indices), is associated with a lower incidence and severity of oral mucositis in patients with hematological 
diseases who receive treatment with chemotherapy or bone marrow transplant.
Study design: The study was carried out on 97 patients admitted to the Hematology Service of the Hospital Duran y 
Reynals in Barcelona during 2002-2003. These patients received treatment with chemotherapy or conditioning prior to 
bone marrow transplant. A descriptive study was made, analyzing oral hygiene, one dental index, and two gingivales 
indices, and evaluating their relationship with the appearance of mucositis.
Results: The patients with high plaque (PI) and gingival (GI) indices during chemotherapy presented a higher percen-
tage of mucositis (77.4% and 65.7% respectively) against those who had little or no visible plaque. In the case of the PI, 
the differences were statistically significant (p=0.015). Likewise, patients who brushed their teeth 3 times/day presented 
mucositis in only 26.7% of cases, against those who did not brush, or brushed only once a day (65.9% and 68.4%), these 
differences also being statistically significant (p=0.013). The CAO showed similar results in patients with or without 
mucositis (7.59 and 7.03 respectively).
Conclusions: In our study, a good gingival status as well as good oral hygiene during chemoradiotherapy is associated 
with a lower incidence and severity of mucositis.  
Key words: Malignant hematological diseases, chemoradiotherapy, mucositis, buccodental status.
RESUMEN
El objetivo del presente trabajo fue valorar si un buen estado buco-dental (valorado mediante índices dento-gingivales), 
se asociaba a una menor incidencia y gravedad de mucositis oral en pacientes con enfermedades hematológicas que iban 
a recibir tratamiento con quimioterapia o un trasplante de médula ósea.
Diseño del estudio: El estudio se llevó a cabo en 97 pacientes ingresados en el Servicio de Hematología del Hospital 
Duran y Reynals en Barcelona en los años 2002-2003. Estos pacientes recibían tratamiento con quimioterapia o bien el 
acondicionamiento previo a un trasplante de médula ósea. Se realizó un estudio descriptivo analizando un índice dental, 
dos índices gingivales y la higiene oral y su relación con la aparición de mucositis.
Resultados: Los pacientes que durante la quimioterapia mostraron valores elevados del índice de placa (IP) y gingival (IG) 
presentaron un mayor porcentaje de mucositis (77.4% y 65.7% respectivamente) frente a los que tenían poca placa o ésta 
no era visible. En el caso del IP las diferentas fueron estadísticamente significativas (p=0.015). Asimismo los pacientes 
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INTRODUCTION
Oral mucositis is one of the most frequent side effects of 
oncological treatment. The prevalence oscillates between 
30-70% after chemotherapy, and can increase to 90% in the 
case of a bone marrow transplant (1-3). It is a significant 
cause of morbidity during antineoplastic therapy. It affects 
the patient’s quality of life since it proceeds with intense pain 
and ulcers that hinder feeding, swallowing and speech (1,3). 
Likewise, it is associated with prolonged fever, parenteral 
alimentation, administration of opiates, and a higher risk 
of infection (4,5). 
Mucositis is an inflammatory reaction that affects the entire 
gastrointestinal tract, although with a greater involvement 
of the oropharyngeal area. Clinically it appears between 
approximately the fifth and seventh day from the start of 
chemotherapy, the lesions being located fundamentally 
in the non-keratinized oral mucosa (1,6). In patients who 
receive a bone marrow transplant (BMT), the lesions can 
begin at 24 to 48 hours of the infusion (7).
Mucositis can present different grades of severity, from a 
minimal erythema, edema or burning sensation, to large and 
painful ulcers that limit basic oral functions and can even 
interrupt the oncological treatment (7-9).  
The etiopathogenesis of mucositis is not entirely clear. Clas-
sically, it has been linked to the so-called “theory of direct-
indirect toxicity”, by which, on the one hand, the mucositis 
would result from the direct action of the chemotherapy 
on the cells of the basal layer of the epithelium, and on the 
other, it would be due to the secondary myelosuppression 
of the oncological treatment (10). At the end of the nineties, 
Sonis (2) established a new etiopathogenic hypothesis in 
which he described mucositis as a complex biological process 
that would proceed in four phases: inflammatory / vascular, 
epithelial, ulcerative / bacterial and healing phase. This is the 
current hypothesis, and diverse authors are carrying out in-
depth investigations into the characteristics of the different 
cellular and molecular phenomena that are produced.
In addition, a series of risk factors have been described in 
association with the appearance of mucositis, among whi-
ch, those related with the chemotherapy regime and those 
related with the individual (age, nutritional, buccodental 
and hematological status among others) are highlighted 
(1,4,10). On the other hand, it has been suggested that 
mucositis would not only affect the epithelium, but rather 
some cellular and molecular phenomena would be located 
in the submucosa, principally the vascular endothelium 
(2,4). Recent studies also point out a possible genetic basis 
for the appearance and severity of mucositis (1).
It has been demonstrated that the type of  chemothera-
peutic regime is a very important factor in relation to the 
appearance of mucositis, so much so that some authors 
(3,6,10) describe it as an independent risk factor. Regimes 
that involve busulphan, melphalan, cyclophosphamide, 
and etoposide, or conditioning prior to BMT in which the 
patient also receives the so-called total body irradiation 
(TBI), present elevated stomatotoxicity (4,5,10).
Regarding patient-dependent factors, we focus on the buc-
codental status. Some studies have associated the condition 
of the oral cavity to the appearance of mucositis (2,6,11). 
However, few studies exist that objectively evaluate oral 
health during chemotherapy. Most studies have been carried 
out by nursing staff who have assessed oral hygiene protocols 
and oral care (12,13), or by oncologists or interns (14-16), 
there being very few that register dental or gingival indices 
(17,18). In most cancer hospitals, the patient is usually 
recommended to visit the stomatologist before beginning 
chemoradiotherapy. However, in many cases the urgency 
to begin treatment of the basic disease means that it is not 
possible to carry out all the required odontological treat-
ment. On the other hand, maintaining the oral cavity under 
the best hygienic conditions and with minimum gingival 
inflammation during oncological treatment should lead to 
fewer mucosal complications (7).
The above argument and the lack of studies in relation to 
this topic have motivated this clinical study of oral mucositis 
and its association with the buccodental status.
OBJECTIVES
The objective of this study was to verify if  a good buccoden-
tal condition (correct oral hygiene, absence of cavities, den-
tal plaque and gingival inflammation) during oncological 
treatment is associated with a lower incidence and severity 
of oral mucositis in patients with hematological disease who 
receive chemotherapy or a bone marrow transplant.
STUDY DESIGN
The study was carried out in the Hematology Service of the 
Hospital Duran y Reynals, Barcelona between May 2002 
and December 2003.
The sample was made up of 97 patients diagnosed with 
some type of hemopathy and scheduled to receive treatment 
with standard chemotherapy or conditioning prior to bone 
marrow transplant.
This is a descriptive, longitudinal study. Descriptive statis-
tics of the sample and the clinical findings were performed, 
calculating the different means and their corresponding 
que cepillaban los dientes 3veces/día sólo presentaron mucositis en un 26.7% de los casos, frente a los que no cepillaban 
o lo hacían una vez al día (65.9% y 68.4%), siendo estas diferencias también estadísticamente significativas (p=0.013). 
El ICAO mostró resultados similares en los pacientes con o sin mucositis (7.59 y 7.03 respectivamente).
Conclusiones: En nuestro trabajo, un buen estado gingival así como una buena higiene oral durante la quimiorradiote-
rapia, se asocian a una menor incidencia  y gravedad de mucositis.  
Palabras clave: Enfermedades hematológicas malignas, quimiorradioterapia, mucositis, estado buco-dental.
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standard deviations with a confidence interval of 95%. The 
chi-square test was used for qualitative variables and the 
Student’s t-test for the quantitative variables in the analysis 
of possible associations between mucositis and the indepen-
dent variables, with a significance level of 0.05%.
The data were collected in an Excel table and the statistical 




Patients participating in the study had previously been 
admitted to the hospital Hematology Service. Informed 
consent was given prior to being included in the study. The 
inclusion criteria were as follows: aged over 17 years, male 
or female, diagnosed with hematological disease, treatment 
with chemotherapy and/or BMT, voluntary participation 
in the study. The following exclusion criteria were selected: 
serious deterioration in general health, low cognitive level, 
simultaneous presence of any mucocutaneous disease, graft 
versus host disease, and refusal to participate in the study.
Methods
The visit to the patients was programmed for the seventh 
day following initiation of chemotherapy or conditioning 
for BMT. A special protocol was designed to register the 
data obtained. Both the anamnesis and the buccodental 
exploration were performed by the same examiner in all pa-
tients with the purpose of reducing any possible subjectivity. 
Examinations were carried out in the patient’s own room 
or in the ITU (Intensive Therapy Unit), with the patient 
either in bed or sitting in a chair. For the examination of the 
oral cavity, we used: gloves, mask, dental light for intraoral 
illumination and a WHO sterile examination set containing 
two dental mirrors, some dental forceps, an examination 
probe and a periodontal probe.
In the anamnesis, the following fundamental data were 
registered: age, sex, hematological disease, chemotherapy 
regime, BMT and type, other systemic diseases, drug treat-
ments and analytic parameters. 
The buccodental state was evaluated by means of the fo-
llowing indices:
- CAOD index (19)
- Silness-Löe plaque index (20)
- Löe-Silness gingival index (20)
- Oral hygiene (good, 3 times a day; regular, twice a day; bad, 
once or not at all) supervised by the hospital nursing staff
Furthermore, other parameters were registered:
- The type of mouthwash used by the patient
- The oral pain measured on a visual analogical scale (VAS) 
(0-no pain, 10-maximum pain)
- The degree of mucositis according to the WHO classifi-
cation (21)
When carrying out the statistical analysis of the data for 
both the plaque and the gingival indices, because of the low 
number of patients in each of the grades it was decided to 
regroup the different categories of variables. The variables 
were regrouped as follows: Plaque index (PI) - 2 groups: 
patients with visible or abundant plaque, and patients with 
no visible plaque or without plaque, gingival index (GI) - 2 
groups: patients with healthy gums or slight inflammation, 
and patients with moderate or severe inflammation.
RESULTS
Of the 97 patients that participated in the study, 47 were 
male (48.5%) and 50 female (51.5%). The mean age was 
of  48.5 years, standard deviation15.25 years, and range 
17-72.
The most frequent hematological diseases present in the 
sample were acute myeloid leukemia (37.1%), non-Hodgkin’s 
lymphoma (20.6%) and multiple myeloma (12.4%). To a 
lesser degree: chronic myeloid leukemia and the Hodgkin’s 
lymphoma, (7.2% each one) medullary aplasia and acute 
lymphatic leukemia (6.2% each one) and finally chronic 
lymphocytic leukemia (3.1%).
The most used chemotherapeutic regimes were DAE (dau-
norubicin, ara-C, etoposide) (26.8%), followed by CHOP 
(cyclophosphamide, doxorubicin, leurocristine (vincristine 
sulfate), prednisone), IDICE (idarubicin, cyclophospha-
mide, etoposide) and busulphan / melphalan (14.4% each 
one respectively). 
Of the 97 patients, 42 (43.3%) received a bone marrow 
transplant, while the remaining 55 (56.7%) did not. Of the 
42 transplants, 22 were autologous and 20 allogenic.
Evaluating of pain on the VAS obtained the following re-
sults: the initial mean pain was 2.75 with a median of 2.0 
and a standard deviation of 2.44. Twenty-eight percent of 
patients were not in pain during the visit.
Regarding the type of mouthwash, 27.8% of patients were 
not using mouthwash at the time of the visit, while the re-
maining 72.2% were. Of these, 38.1% used bicarbonate and 
32.0% used multiple mouthwashes (bicarbonate, chamomile, 
chlorhexidine, nystatin).
The results of the descriptive study of the mucositis are 
described below. The appearance of mucositis is described 
both in function of the chemotherapy regime and in relation 
with the dental and gingival indices, and oral hygiene.
The prevalence of mucositis in our study was 60.8%. Most 
patients (44.3%) only presented erythema / edema (WHO 
grade I), while the most serious forms (WHO grades II, 
III, IV) appeared less frequently (7.2%, 6.2%, 3.1% res-
pectively).
The relationship between mucositis and chemotherapy 
regime: the patients treated with busulphan / melphalan pre-
sented mucositis in 71.4% of cases, followed by the IDICE, 
DAE and CHOP regimes with percentages of 64.3%, 61.5% 
and 57.1% respectively. However, the differences were not 
statistically significant.
Relationship between mucositis and CAO index: the CAO 
index for patients with mucositis was 7.59 and 7.03 for 
those without it. The differences were not statistically 
significant.
Relationship between mucositis and plaque index (PI): pa-
tients without plaque presented mucositis in 48.0% of the 
cases; patients with no visible plaque presented mucositis 
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in 55.0%; patients with visible plaque, 77.8%; and patients 
with abundant plaque, 75.0%. Given the low number of 
patients in each group and the clear tendency for patients 
with visible or abundant plaque to present higher mucositis 
percentages, the data for this variable was grouped into two 
categories: patients with visible or abundant plaque and 
patients with no or no visible plaque. The patients with 
visible or abundant plaque presented mucositis in 77.4%, 
on the other hand those with no plaque or where this was 
not visible, presented mucositis in only 52.3% of cases. This 
difference was statistically significant (p=0 .015).
Relationship between mucositis and gingival index (GI): 
patients with healthy gums presented mucositis in 46.2% of 
cases; patients with slight inflammation, in 60.0%; patients 
with moderate inflammation, 69.2%; and patients with seve-
re inflammation, presented 100% mucositis. In this case, and 
also for the same reasons, the variable was grouped into two 
categories. Thus, the patients with gingival inflammation 
presented 65.7% mucositis; and the patients with healthy 
gums presented 46.2% mucositis. Despite this tendency, the 
differences were not significant (p=0 .067).
Relationship between mucositis and oral hygiene: patients 
with good oral hygiene presented mucositis in only 26.7% 
of cases. Those with poor oral hygiene presented in 65.9% 
of cases and those with normal oral hygiene in 68.4%. These 
differences were statistically significant (p=0 .013).
Relationship between mucositis and oral mouthwashes: 
patients who did not use mouthwash, presented only 37% 
mucositis. On the other hand, mucositis did appear in 71% 
of those who used multiple mouthwashes and in 67.6% of 
those who rinsed with bicarbonate, with statistically signi-
ficant differences (P=0 .015).
DISCUSSION
Chemotherapy and/or BMT are the current treatments for 
diverse types of malignant diseases, not just hematological, 
because of the good therapeutical results offered.  For this 
reason, the number of patients subjected to these therapies 
has increased in recent years, and the control and handling 
of its complications is fundamental. Given that the oral 
cavity is one of the most frequent locations for side effects 
of chemoradiotherapy, and one that causes the patient much 
discomfort, a close collaboration aimed at minimizing these 
effects should exist between the stomatologist and the other 
health-care professionals involved in treating the patient.
The prevalence of mucositis found in our study was 60.8%. 
This high frequency corresponds with that referred by 
other authors such as Epstein et al. (1), Gabriel et al. (4) 
or Sonis (2). 
We observed no significant differences between the type 
of  chemotherapy regime and the presence of  mucositis. 
However, there is a tendency for patients treated with 
certain cytostatics to present a higher rate of  mucositis, 
as was found in the case of regimes based on busulphan / 
melphalan, results that coincide with those of Wardley et 
al. (5) and Barasch et al. (10).
When it comes to evaluating the remaining results, we find 
ourselves, as mentioned in the introduction, with few optio-
ns. On one hand, few studies in the literature evaluate the 
gingival and dental status, and on the other, the existence 
of different classifications for mucositis can occasionally 
hinder the comparison. In our study, we have used the WHO 
classification (21), one of the most used, especially in clinical 
studies (0: normal mucosa, 1: erythema, edema, 2: erythema, 
small aphthae, 3: large ulcers, only liquids allowed, 4: large 
ulcers, pseudomembranes, ingestion is not possible). 
The mean CAOD index in our study did not show significant 
differences in connection with the presence of mucositis. In 
any case, it is well known that patients with active caries, 
radicular remains and septic foci of dental origin, have a 
higher risk of presenting pain and oral infections during 
chemotherapy (mainly in the neutropenic phase). We also 
highlight that the CAO index value of 7.73 found in the 
current study is somewhat lower than that observed in a 
study published by our group in 2000: 10.7 (17).
Some studies have tried to evaluate the oral state noting 
parameters such as visits to the dentist or oral treatments 
received. Dodd et al. (13), registered a mean of 15 months 
from the last visit to the dentist and 10.7 months since the 
last scaling in a group of 50 breast and colon cancer patients 
who developed mucositis during chemotherapy, which could 
give some idea of the possible presence of dental alterations, 
calculus and plaque. Epstein et al. (1), point out that oral 
hygiene, and thus the removal of dental plaque, would be 
an indirect form of reducing the risk of bacteremia and 
periodontitis.
With regard to studies registering dental or gingival indices 
and their relationship with mucositis, we will comment on 
two: that of the year 2000 mentioned above, and another 
from 2002. In the first, López et al. (17) observed a decrease 
of PI and GI (significant in the case of GI) in patients who 
attended the dentist before beginning chemotherapy. In the 
second, Lugliè et al. (18) carried out a scaling or curettage 
and administered a 0.2%chlorhexidine mouthwash to 27 
patients, obtaining a statistically significant decrease for 
both PI and GI during chemotherapy against a control 
group. Mucositis presented in only 20% of patients in their 
treatment group. On the other hand, McCarthy et al. (22), 
in patients with solid tumors, observed results contrary to 
most studies, included ours, finding no relationship between 
oral hygiene and accumulated plaque, and the presence of 
mucositis.
A highly controversial topic is that of  dental brushing 
during chemotherapy since many hospitals prohibit it be-
cause of the possible risk of bacteremia and bleeding in the 
neutropenia and platelet deficiency phases. In the present 
study, we evaluate oral hygiene in function of the number 
of times per day that the patient brushes. We were aware of 
the probable subjectivity of the parameter and that it could 
depend on the individual’s own ability; although brushing 
teeth more than once a day should, in our opinion, usually 
indicate greater interest by the patient for their oral hygiene 
and thus better plaque removal. The Greene Vermillion, 
1960 oral hygiene index (OHI) (20) was not used since it 
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requires a dual evaluation: the extent of debris and of tartar, 
the scale is similar to the plaque index and its values increase 
with age. The significant result we observed in patients who 
brushed 3 times a day from the beginning of chemotherapy, 
is close to that of authors such as Kennedy et al. (15), Cheng 
et al. (23), and Bonnaure-Mallet et al. (24), the last two in 
an infant population. 
It has also been observed that good oral hygiene that in-
cludes dental brushing reduces the incidence and severity 
of mucositis without increasing the risk of bacteremia, not 
even in neutropenic patients, since the presence of plaque 
and abundant calculus are considered potentially more 
dangerous (7,15,23). However, these authors point out that 
once used, the dental brush is quickly colonized by oral 
bacteria and they therefore recommend discarding the brush 
after each use or soaking in a 2% chlorhexidine solution 
and rinsing in sterile saline serum before reuse. Stiff  (25) 
on the other hand, does not recommend brushing during 
the post-transplant mucositis phase, although they would 
allow antiseptic mouthwashes and anesthetics. Epstein et 
al. (26), affirm that the 25-50% sepsis in immunocompro-
mised patients originates in the oral cavity, although they 
do not observe that brushing per se increases the risk of 
bacteremia.
The use of an oral mouthwash during chemotherapy, either 
preventatively or as treatment, is widespread. In fact, it 
forms part of the preventive and therapeutic protocol for 
the oral complications of chemoradiotherapy in most can-
cer hospitals. However, the literature does not recommend 
their widespread use, since in many cases there is limited 
scientific evidence for their effectiveness (1,8,27). Kenny 
(12) compares two protocols for oral care in hematological 
patients, one with bicarbonate and the other with saline 
serum finding no differences between them with regard to 
evolution of mucositis. Furthermore, the topical application 
of 0.2% chlorhexidine in aqueous solution has been used 
in different studies with controversial results. Pitten et al. 
(28) in leukemia patients and Dodd et al. (13) in patients 
with breast and colon neoplasia observed that using chlor-
hexidine reduced neither the incidence nor the severity of 
the mucositis. Pitten (28) also points out, the possibility 
of side effects such as irritation of the oral mucosa and 
dental staining, although he indicates that chlorhexidine 
would reduce the oral microbial load. On the other hand, 
Rutkauskas et al. (29) obtained positive results for mucositis 
after administering chlorhexidine mouthwash in patients 
who were to receive a BMT, and Lugliè et al. (18), refer 
that chlorhexidine could have influenced the reduction of 
the mucositis observed in their study, although the patients 
also received periodontal treatment. In addition, Caribé 
et al. (30) include chlorhexidine in their protocol for the 
treatment of mucositis secondary to radiation therapy in 
patients with oral cancer.
In our study, patients that did not use mouthwash developed 
less mucositis than those who used multiple mouthwashes 
(chlorhexidine, bicarbonate, camomile, fungicidin/nystatin). 
These results, which at first sight may seem contradictory, 
would indicate that patients who rinsed presented a more 
serious oral mucositis and therefore more oral symptoma-
tology, and to reduce this would we believe use all available 
solutions. That is to say, it would be a typical example of 
a non-causal relationship, in that possibly those patients 
who did not present mucositis, did not need to use a 
mouthwash, and not that the mouthwash was the cause of 
the mucositis.
CONCLUSIONS
In conclusion, it should be emphasized that from the 
results obtained in our study, maintaining a healthy oral 
cavity during oncological treatment, with little plaque or 
gingival inflammation, is a factor that would condition a 
lower and less serious incidence of mucositis. In addition, 
dental brushing becomes the most effective method for the 
removal of dental plaque. 
On the other hand, we believe further studies where the buc-
codental status and mucositis are randomly evaluated over 
time with a larger group of patients are necessary. Likewise, 
it is essential to deepen our studies of the remaining risk 
factors and the etiopathogenesis of mucositis, since better 
understanding will help to develop new treatments in the 
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